Genetic variants on chromosome 19 (rs439401 and rs4420638) are associated with obesity and high blood pressure in the Algerian population

Metabolic syndrome (MetS) represents a combination of at least three primary metabolic abnormalities from among obesity, hyperglycemia, dyslipidemia, and high blood pressure, once combined, they increase significantly the cardiovascular risk. The APOE gene is considered as a genetic risk factor for cardiovascular diseases, it has been linked to MetS or its traits in several populations. Our study aimed to analyze the association of three APOE gene polymorphisms with MetS risk and its components in a general population sample, and to highlight the potential influence of these polymorphisms on individual susceptibility to MetS. We performed this work using a population-based, cross-sectional study of a representative sample of 787 individuals (378 men and 409 women, aged between 30 and 64 years) recruited in the city of Oran, Algeria (the ISOR Study); the subjects were genotyped for four polymorphisms, rs7412, rs429358, rs4420638 and rs439401, located in the APOE gene, using the KASPar technology. rs439401 showed a significant association with hypertension (HBP). The T allele confers a high risk of hypertension with an odds ratio (OR) of 1.46 (95 % CI [1.12–1.9], p = 0.006). rs4420638 was significantly associated with obesity in the general population. The G allele provides protection against obesity, the resulting OR is 0.48 (95 % CI [0.29–0.81], p = 0.004). Although APOE variants were not associated with the risk of MetS, the APOE polymorphism alleles were associated with some of the metabolic parameters in Algerian subjects. The relation of APOE rs439401 alleles with a HBP is likely to be indicative of a state of stress of the population.

1. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome¬a new worldwide definition. [Research Support, Non¬U.S. Gov’t]. Lancet. 2005;366(9491):1059-1062.

2. Aulchenko Y.S., Ripatti S., Lindqvist I., Boomsma D., Heid I.M., Pramstaller P.P., Penninx B.W.J.H., Janssens A.C.J.W., Wilson J.F., Spector T., Martin N.G., Pedersen N.L., Kyvik K.O., Kaprio J., Hofman A., Freimer N.B., Jarvelin M.-R., Gyllensten U., Campbell H., Rudan I., Johansson Å., Marroni F., Hayward C., Vitart V., Jonasson I., Pattaro C., Wright A., Hastie N., Pichler I., Hicks A.A., Falchi M., Willemsen G., Hottenga J.-J., de Geus E.J.C., Montgomery G.W., Whitfield J., Magnusson P., Saharinen J., Perola M., Silander K., Isaacs A., Sijbrands E.J.G., Uitterlinden A.G., Witteman J.C.M., Oostra B.A., Elliott P., Ruokonen A., Sabatti C., Gie¬ ger C., Meitinger T., Kronenberg F., Döring A., Wichmann H.¬E., Smit J.H., McCarthy M.I., van Duijn C.M., Peltonen L., for the ENGAGE Consortium. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 2009;41:47-55.

3. Balkau B., Valensi P., Eschwege E., Slama G. A review of the metabolic syndrome. Diabetes Metab. 2007;33(6):405-413.

4. Boer J.M., Ehnholm C., Menzel H.J., Havekes L.M., Rosseneu M., O’Reilly D.St.J., Tiret L., and for the EARS Group. Interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins. Arterioscler. Thromb. Vasc. Biol. 1997;17(9):1675-1681.

5. Boulenouar H., Benchekor S.M., Meroufel D.N., Hetraf S.A.L., Djellouli H.O., Hermant X., Grenier-Boley B., Medjaoui I.H., Mehtar N.S., Amouyel P., Houti L., Meirhaeghe A., Goumidi L. Impact of APOE gene polymorphisms on the lipid profile in an Algerian population. Lipids Health Dis. 2013;12:155.

6. Chalmers J., MacMahon S., Mancia G., Whitworth J., Beilin L., Hansson L., Neal B., Rodgers A., Ni Mhurchu C., Clark T. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin. Exp. Hypertens. 1999; 21(5-6):1009-1060.

7. Chuang L.M. Human genetics of the metabolic syndrome. Asia Pac. J. Clin. Nutr. 2008;17(Suppl.1):43-46.

8. Elouej S., Rejeb I., Attaoua R., Nagara M., Sallem O.K., Kamoun I., Chargui M., Jamoussi H., Turki Z., Abid A., Ben Slama C., Bahri S., Ben Romdhane H., Abdelhak S., Kefi R., Grigorescu F. Gender¬ specific associations of genetic variants with metabolic syndrome components in the Tunisian population. Endocrin. Res. 2016;41(4): 300-309.

9. Gami A.S., Witt B.J., Howard D.E., Erwin P.J., Gami L.A., Somers V.K., Montori V.M. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 2007;49(4):403¬414.

10. Gavin J.R., 3rd. New classification and diagnostic criteria for diabetes mellitus. Clin. Cornerstone. 1998;1(3):1-12.

11. Grundy S.M., Brewer H.B., Jr., Cleeman J.I., Smith S.C., Jr., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109(3):433-438.

12. Hillier T.A., Rousseau A., Lange C., Lépinay P., Cailleau M., Novak M., Calliez E., Ducimetière P., Balkau B. Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis. Diabetologia. 2006;49(7):1528-1535.

13. Houti L., Hamani-Medjaoui I., Lardjam-Hetraf S.A., Ouhaibi-Djellouli H., Chougrani S., Goumidi L., Mediene-Benchekor S. Prevalence of metabolic syndrome and its related risk factors in the city of Oran, Algeria: the ISOR Study. Ethn. Dis. 2016;26(1):99-106.

14. Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28(9):2289-2304.

15. Kathiresan S., Melander O., Guiducci C., Surti A., Burtt N.P., Rieder M.J., Cooper G.M., Roos C., Voight B.F., Havulinna A.S., Wahlstrand B., Hedner T., Corella D., Tai E.S., Ordovas J.M., Berglund G., Vartiainen E., Jousilahti P., Hedblad B., Taskinen M.¬R., Newton-Cheh C., Salomaa V., Peltonen L., Groop L., Altshuler D.M., Orho-Melander M. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 2008;40:189-197.

16. Kring S.I., Brummett B.H., Barefoot J., Garrett M.E., Ashley¬Koch A.E., Boyle S.H., Siegler I.C., Sørensen T.I.A., Williams R.B. Impact of psychological stress on the associations between apolipoprotein E variants and metabolic traits: findings in an American sample of caregivers and controls. Psychosom. Med. 2010;72(5):427-433.

17. Meigs J.B., Rutter M.K., Sullivan L.M., Fox C.S., D’Agostino R.B., Sr., Wilson P.W. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30(5):1219-1225.

18. Ministère de la Santé, de la population et de la réforme hospitalière. In: Transition épidémiologique et système de santé. Projet TAHINA Résultats Enquête Nationale Santé. 2007.

19. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.

20. Talmud P.J. Gene¬environment interaction and its impact on coronary heart disease risk. Nutr. Metab. Cardiovasc. Dis. 2007;17(2):148-152.